• Contact Us
  • About
  • Advertise
  • Careers
Kashmir Dot Com
  • Home
  • Kashmir
  • Jammu
  • World
  • Politics
  • Opinion
  • Business
  • Health
  • Contact Us
No Result
View All Result
  • Home
  • Kashmir
  • Jammu
  • World
  • Politics
  • Opinion
  • Business
  • Health
  • Contact Us
No Result
View All Result
Kashmir Dot Com
No Result
View All Result
Home Health

Centre Flags Carcinogen Fears On Acidity Medicine Ranitidine, Orders Probe

Kashmir Dot Com by Kashmir Dot Com
July 27, 2025
in Health
0
Centre Flags Carcinogen Fears On Acidity Medicine Ranitidine, Orders Probe

File Image

0
SHARES
136
VIEWS
Share on Facebook

New Delhi: The Central Drugs Standard Control Organisation (CDSCO) has directed all state and union territory drug regulators to ensure manufacturers of Ranitidine — a commonly used acidity medicine –monitor NDMA levels, a potentially cancer-causing impurity, in both the active pharmaceutical ingredient (API) and formulations of the drug. The CDSCO has also suggested reducing the shelf life as a precautionary step.

The move comes from the Drugs Controller General of India (DCGI), Dr Rajeev Singh Raghuvanshi, following a recommendation by the Drugs Technical Advisory Board (DTAB) during its 92nd meeting on April 28, 2025.

The Board reviewed a report submitted by an expert committee constituted in December last year to study the impurity concerns around Ranitidine. Based on this, DTAB has called for a larger committee to examine all aspects of the issue, including storage conditions that may contribute to NDMA formation.

In addition, the Board recommended that the Indian Council of Medical Research (ICMR) conduct a study to further assess the long-term safety of Ranitidine in light of NDMA presence.

Manufacturers have now been told to adopt risk-based measures, such as limiting shelf life, modifying storage recommendations, and enhancing NDMA testing protocols across their supply chains.

“Ranitidine falls in the Group 2A carcinogen category, according to the International Agency for Research on Cancer (IARC), which implies that it is a probable human carcinogen. It should not be continued in prescription when there are safer alternatives such as Famotidine and Pantoprazole available,” said Dr Abhishek Shankar, Oncologist, AIIMS Delhi.

NDMA is classified as a probable human carcinogen, and its presence in medications has triggered global regulatory scrutiny over recent years. Ranitidine, commonly prescribed for acid reflux and ulcers, was withdrawn from several markets, including the US, after alarmingly high levels of NDMA were found in some samples.

“Ranitidine was commonly prescribed in the past. Its usage has reduced in most metro cities, but it is still prescribed in Tier 1 or 2 cities, particularly at primary healthcare centres. In my knowledge, the drug has been known to have NDMA impurities; the FDA has also ruled out the use of this drug in large doses. The DGCI needs to set prescribed limits for NDMA levels in this drug,” said Dr Lohit Chauhan, Gastroenterologist at Max Dwarka.

Tags: RanitidineTrending
Previous Post

CM Omar Abdullah hails Kashmir University’s legacy at Mega Alumni Meet-2025

Next Post

Sakeena Itoo conducts surprise inspection of district hospital Pulwama

Next Post
Sakeena Itoo conducts surprise inspection of district hospital Pulwama

Sakeena Itoo conducts surprise inspection of district hospital Pulwama

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

ADVERTISEMENT

LATEST NEWS

Centre Transfers Three IAS Officers from Delhi to Jammu and Kashmir

J&K SEC Shantmanu attends meeting with President at Rashtrapati Bhavan

Spl Secy Cabinet Secretariat reviews deregulation reforms with Chief Secretary Dr. Sajjan

IndiGo cancels Saudi Arabia flights till Nov 30

FDA Seals Hattrick’s Storage Area in Rajbagh Over Food Safety Violations; 69 Inspections Conducted Across J&K

JKSA Slams BGSBU VC Over Invitation to RSS Pracharak Indresh Kumar as Chief Guest, Seeks Probe

SMC Seals Unauthorised Car Washing Centre in Srinagar’s Natipora

NIT Srinagar selects three teams for National-Level Design for Bharat 2027 challenge

Article 21 means nothing but lip service if police fancy dictates preventive detention: J&K High Court

Only Handful of Foreign Terrorists Remain in J&K, UT Will Soon Be Terror-Free: LG Sinha

Facebook Twitter

About Us

Kashmir Dot Com (KDC) is J&K's premier News Agency having a vast reach of audience.

Kashmir Dot Com is a News Agency based in Srinagar, J&K that offers syndicated multimedia news feed to plethora of news-bureaus in J&K and beyond. We also provide a range of facilities from foreign and domestic channels to package their reports in Jammu and Kashmir. We cover almost all areas of interest in J&K to viewers including news, entertainment, and life styles, bussiness, sports, human-interest features and social and developmental issues.

KDC can well and truly take pride in the legacy of it's work, and in it's contribution towards the building of a free and fair Press in Jammu and Kashmir.

Category

  • Business
  • Entertainment
  • Health
  • JAMMU
  • Kashmir
  • Lead
  • National
  • Opinion
  • Politics
  • Science
  • Sports
  • Tech
  • Uncategorized
  • World

Company Info

  • Contact Us
  • About
  • Advertise
  • Careers

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.

error: Content is protected !!
No Result
View All Result
  • Home
  • Kashmir
  • Jammu
  • World
  • Politics
  • Opinion
  • Business
  • Health
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.